Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fimasartan/HCTZ combination · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Fimasartan/HCTZ combination group | EXPERIMENTAL | - |
| Fimasartan group | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Fimasartan/HCTZ combination | DRUG | Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg |
| Fimasartan | DRUG | Fimasartan 60mg, 120mg |
Inclusion Criteria: * Male and female outpatients 18 years of age and older * Patients with antihypertensive agents at screening: DBP\<110mmHg or Patients without antihypertensive agents at screening: DBP 90mmHg\~120mmHg * Subjects who agree to participate in this sudy and give written informed con...
Fimasartan is an investigational small molecule being developed for the treatment of hypertension, including essential hypertension. It is a cardiovascular therapeutic currently in Phase 3 clinical development. Fimasartan has been studied in clinical trials for its antihypertensive efficacy and safety in patients with hypertension.
Fimasartan is being developed by National Healthcare Corp., a company listed under the ticker NHC. The drug is currently in Phase 3 clinical development for the treatment of hypertension and essential hypertension.
Fimasartan is in Phase 3 clinical development. It has completed two Phase 3 trials and one Phase 2 trial, all of which were randomized, double-blind, and placebo-controlled. Fimasartan is not yet approved and remains investigational.
Fimasartan has completed several clinical trials, including NCT00922480, a Phase 3 study in hypertension patients with 506 participants, and NCT01258673, a Phase 3 study of Fimasartan in combination with hydrochlorothiazide for essential hypertension with 263 participants. A Phase 2 trial, NCT00923611, enrolled 182 patients with mild to moderate essential hypertension.
Fimasartan is the single-agent drug, while Fimasartan/Hydrochlorothiazide is a combination therapy that includes Fimasartan plus hydrochlorothiazide. The combination has been studied in a Phase 3 clinical trial for essential hypertension, but it is a separate formulation from Fimasartan alone.
Fimasartan is a small molecule antihypertensive agent. Its specific molecular target has not been disclosed in the available clinical trial information. It is being studied for its ability to lower blood pressure in patients with hypertension and essential hypertension.